ClinicalTrials.gg
CompletedNCT05649722Updated Apr 23, 2026

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2/3 interventional study of Treprostinil Palmitil Inhalation Powder and Placebo in Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Insmed Incorporated. Completed at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Insmed Incorporated · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies in Hypertension, Pulmonary with a site in Germany — 21 open to participants now, 28 under way, 6 of them phase 3. Hypertension, Pulmonary · Germany.

Enrollment
81st of 105
31 · median 86
Started
2023
with 8 others
Phase 2/3
2 of 150
none open now
Registered
131st of 150
by date
Lead sponsor
4 of 150
Insmed Incorporated

Among the 150 studies in Hypertension, Pulmonary with a site in Germany, this one is the 81st largest by enrollment of the 105 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 in phase 2/3, and was the 131st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

21 of the 150 studies in Hypertension, Pulmonary with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertension, Pulmonary with a site in Germany, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.

03

Conditions studied

  • Pulmonary Hypertension
  • Interstitial Lung Disease

Keywords

  • Treprostinil Palmitil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed the end of treatment visit in Study INS1009-211 (NCT05176951). Participants for whom the OLE study was not available at the time of their completion of the lead-in study are eligible for enrolment within one year of their lead-in end of treatment visit.
  • Complete baseline screening assessments to confirm eligibility to participate if more than 30 days have elapsed since the end of the study visit in Study INS1009-211, or any other lead-in PH-ILD TPIP study.
  • Capable of giving signed that includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Participants who experienced any or adverse drug reaction or were withdrawn early/discontinued in a previous PH-ILD TPIP study, which in the opinion of the Investigator, could indicate that continued treatment with TPIP may present an unreasonable risk for the participant.
  • Initiation of parenteral administration of prostacyclin analogues (eg, TRE, epoprostenol) since the completion of Study INS1009-211 or other TPIP studies. Initiation of inhaled prostacyclin analogues (eg, TRE [Tyvaso] or iloprost) and oral prostacyclin analogues (eg, TRE [Orenitram]) or receptor agonists (eg, selexipag) are permitted if stopped 24 hours prior to the start of study drug administration.

Pregnant or breastfeeding. Male and female participants must use that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants of must have a negative urine pregnancy test result at trial entry before the first dose of study drug.

- Any medical or psychological condition, including relevant laboratory abnormalities at screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease that may present an unreasonable risk to the study participant as a result of participation in the study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Treprostinil Palmitil Inhalation Powder

    Participants who are not transitioning immediately from INS1009-211 and other lead-in studies, will be administered TPIP, once daily (QD), during 3-week titration period. Participants who are transitioning immediately from a randomized blinded lead-in TPIP study and who previously received: 1. TPIP- will be administered placebo QD along with the maximum tolerated dose (MTS) TPIP dose from lead-in study in a blinded manner during 3-week titration period. 2. Placebo- will be administered TPIP QD along with the achieved placebo dose from lead-in study in a blinded manner during 3-week titration period. The overall treatment period will be 24 months.

    Drug: Treprostinil Palmitil Inhalation Powder · Drug: Placebo

Interventions

  • Oral inhalation using a capsule-based dry powder inhaler device.

    Also known as: INS1009

  • DrugPlacebo

    Oral placebo inhalation using a capsule-based dry powder inhaler device.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)

    Time frame: Up to approximately 25 months

Secondary outcomes

  1. Absolute Change From Pre-Open-Label Extension (OLE) Baseline in 6-Minute Walk Distance (6MWD)

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  2. Relative Change From Pre-OLE Baseline in 6-MWD

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  3. Change From Pre-OLE Baseline in Forced Vital Capacity (FVC)

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  4. Change From Pre-OLE Baseline in Percent Predicted FVC (FVC%)

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  5. Change From Pre-OLE Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  6. Change From Pre-OLE Baseline in Percent Predicted FEV1 (FEV1%)

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  7. Change From Pre-OLE Baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75%)

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  8. Absolute Change From Pre-OLE Baseline in Lung Diffusion Capacity for Carbon Monoxide (DLCO)

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 12 and 24

  9. Relative Change From Pre-OLE Baseline in Lung DLCO

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 12 and 24

  10. Change From Pre-OLE Baseline in the Concentration of N-Terminal Fragment B-Type Natriuretic Peptide (NT-proBNP) in Blood

    Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24

  11. Annualized Rate of Clinical Worsening Events Based on Percentage of Participants With Clinical Worsening Events

    Clinical worsening events are defined as one of the following: Hospitalization due to a cardiopulmonary indication; Lung transplantation; Death from any cause; Decrease in 6MWD ≥ 15% from baseline; Directly related to disease under study, at 2 consecutive visits at least 24 hours apart; Need for additional pulmonary hypertension (PH) therapy. Annualized clinical worsening event rate is defined as the total number of clinical worsening events that occurred during the treatment period divided by the total number of participant-years during the treatment period.

    Time frame: Up to Month 24

  12. Annualized Rate of Occurrence of Acute Exacerbations of Underlying Interstitial Lung Disease (AE-ILDs)

    Time frame: Up to Month 24

  13. Change From OLE Baseline in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Score

    Time frame: OLE Baseline (Day 1) to Months 6, 12, 18, and 24

  14. Change From OLE Baseline in the Euro Quality of Life-5 Dimension-5 Level (EQ-5D-5L) Questionnaire Score

    Time frame: OLE Baseline (Day 1) to Months 6, 12, 18, and 24

  15. Plasma Concentration Levels of Treprostinil Palmitil (TP) and Treprostinil (TRE)

    Time frame: OLE Baseline (Day 1), Months 6, 12, 18, and 24

07

Study locations

22 sites
  • ARG003
    Autonomus City of Buenos Aires, Buenos Aires C1280AEB, Argentina
  • ARG001
    Rosario, Santa Fe Province S2013KDS, Argentina
  • AUS005
    Macquarie Park, New South Wales 2109, Australia
  • BEL002
    Liège, 4000, Belgium
  • GER006
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • GER004
    München, Bavaria 81377, Germany
  • GER010
    Giessen, Hesse 35392, Germany
  • GER003
    Essen, North Rhine-Westphalia 45239, Germany
  • GER001
    Dresden, Saxony 01307, Germany
  • GER002
    Berlin, 13125, Germany
  • GER012
    Berlin, 14050, Germany
  • ITA004
    Milan, Lombardy 20123, Italy
  • ITA002
    Monza, Lombardy 20900, Italy
  • ITA001
    Palermo, Sicily 90127, Italy
  • ITA003
    Naples, 80131, Italy
  • ESP003
    Palma, Balearic Islands 07120, Spain
  • ESP009
    Santiago de Compostela, Galicia 15706, Spain
  • ESP007
    Oviedo, Principality of Asturias 33011, Spain
  • ESP005
    Barcelona, 08907, Spain
  • ESP010
    Barcelona, 8035, Spain
  • GBR003
    Clydebank, Glasgow G81 4DY, United Kingdom
  • GBR001
    Sheffield, South Yorkshire S10 2JF, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Apr 2026, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Dec 14, 2022
StartActual
May 11, 2023
Primary completionActual
Apr 1, 2026
CompletionActual
Apr 1, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05649722
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
May 11, 2023
Primary completion
Apr 1, 2026
Completion
Apr 1, 2026
Last update
Apr 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil hexadecyl ester

Start the discussion